Right Ventricular Strain in Detecting Subclinical Right Ventricular Systolic Dysfunction in Psoriatic Arthritis Patients: Relation to Serum Endostatin Level
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- This is an observational study: the protocol does not assign a study treatment.
- Who it may be relevant to
- Registry conditions: Psoriatic Arthritis (PsA), Subclinical Right Ventricular Systolic Dysfunction. Basic parameters: 20 years — 50 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- Egypt
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Overview
The aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain echocardiography
Detailed description
Previous studies evaluated RV strain for detection of subclinical RV affection due to PAH in systemic lupus erythematosus. However , to our knowledge , the study of RV strain and its possible association with serum endostatin to detect subclinical right ventricular systolic dysfunction and its relation to PAH in PsA patient is still a novel. Our aim is to assess early right ventricular systolic dysfunction in psoriatic arthritis patients using RV strain Echocardiography.
To evaluate serum endostatin as an objective biomarker for Pulmonary arterial hypertension.
Primary outcome measures
- Detecting subclinical right ventricular systolic dysfunction in PsA patients [Time frame: Up to 24 months]
Eligibility criteria
Inclusion criteria
- Psoriatic arthritis patients according to CASPAR criteria
- Psoriatic arthritis patients without overt cardiovascular symptoms
- Patients with age between 20 to 50 years of age
Exclusion criteria
- Other systemic autoimmune diseases
- Patients with a history of known valvular disease, atrial fibrillation or any other arrhythmia , heart failure, ischemic cardiomyopathy severe obstructive pulmonary diseases and metabolic syndrome.
- Patients with medical disorders as renal, congenital heart diseases, hematological disorders and cancer patients.
- Patients taking certain drugs that have been confirmed to be risk factors for PAH such as appetite suppressant intake drugs (aminorex, fenfluramine derivatives and benfluorex) and chemotherapeutic agents.
- Family history of myocardial infarction, cerebrovascular disease or sudden death before the age of 65y in females and 55 y in males.
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
Egypt · 1 center
- Ain Shams University — Cairo
Identifiers
NCT: NCT07046312 · MD13/2025